University of Reading creates research unit in Kuwait
Dr Mamoon Al Deyab, associate professor in pharmacy and health services research at Reading school of pharmacy and director of the new research unit, said: "Our objective is to make everyday pharmacy care safer and better."We want to build pharmacists skills, we want to strengthen the workforce in Kuwait and in Berkshire, we want to test practical ideas in real healthcare settings and when they work we turn them into routine practise."Teams in Reading and Kuwait will work together to run joint studies, shared expertise, we will apply for joint grants together and offer real world project for students and practitioners."Dr Ahmad Taqi, chair of the Kuwait Pharmaceutical Association, said: "We are confident this exciting partnership will help to increase the number of specialised pharmacists in Kuwait, expand our scientific output and support evidence-based studies."
You can follow BBC Berkshire and Facebook, X
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
an hour ago
- BBC News
ME patient from Sowerby Bridge welcomes government care plan
A woman living with a disease that causes extreme fatigue has thanked the government for increasing support for those with the month, the Department of Health and Social Care announced a care plan for people with myalgic encephalomyelitis (ME) that included investing in research and offering new training for NHS healthcare Hallgarth, from Sowerby Bridge, welcomed the plan as she felt support had been "severely lacking" in the 14 years since her Hallgarth said at its worst her condition left her bed-bound for months and facing up 50 seizures a day, so the new plan was "wonderful". But she cautioned: "Time will tell because you can say all these things and I think we are so used to hearing empty promises."Ms Hallgarth said she felt like she was not listened to when she first went to the doctor with her symptoms and, after a "process of elimination" following a variety of tests, she was diagnosed with of the daily limitations of the illness, she said: "It impacts on a physical level in terms of mobility, moving around the house, leaving the house..."I use an electric wheelchair or a cane if I am going outside the house."When I was at my worst I was not able to sit up." At that point, Ms Hallgarth said she had to "lie horizontally in the dark for months", unable to tend to her personal care, with her partner and son supporting her."ME can affect you on a very severe level with people on feeding tubes or in hospital, completely reliant on care givers," she her condition is more manageable, Ms Hallgarth runs her own jewellery business, AH Jewellery, according to the Local Democracy Reporting Service. Also referred to as chronic fatigue syndrome (CFS), ME is a complex long-term physical disease which affects many parts of the body, according to ME Research condition affects approximately 390,000 people in the UK, causing debilitating fatigue, sleep problems and difficulties with thinking, concentration and memory. The government's plan also includes new training for health staff and medical students, featuring up-to-date learning resources to increase understanding and ensure signs are not government said this would help combat the stigma faced by people living with ME/CFS, which stemmed from a lack of awareness about the Hallgarth said she welcomed many aspects of the plan including improved education for NHS workers and students, and better care proposed for children diagnosed with said she hoped the move would reduce stigma around ME, but warned: "It is going to take a while for those old attitudes to really shift." Listen to highlights from West Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
BBC News
2 hours ago
- BBC News
Wolverhampton supermarket hosts breast cancer screening unit
A breast cancer mobile screening unit is currently available outside a supermarket in Wolverhampton for women who are eligible for unit, stationed at Sainsbury's at Bentley Bridge until 15 September, marks the first time one has been located at the registered with GP practices in the local area and who are due a screening will receive an invitation by letter to attend the unit, and organisers hope it will encourage more local women to attend their aged 50 to 74 are eligible for breast screening and are invited every three years. The unit is run by the Dudley, Wolverhampton and South West Staffordshire Breast Screening Programme.A spokesperson for City of Wolverhampton Council said: "Attending screening is vital for early detection of breast cancer, which is strongly linked to reduced mortality."Anyone experiencing symptoms of breast cancer - such as a new lump, changes to the skin of the breast or nipple discharge - should not wait for their screening invitation but should instead contact their GP as soon as possible."Councillor Obaida Ahmed said: "Early detection is the best form of defence against cancer, which is why regular screening is so important. It can detect cancers at an early stage."Breast screening saves around 1,300 lives each year in the UK, and finding cancer early can make it more likely that treatment will be successful."Anyone who is invited for a screening appointment but is unable to attend their allocated time is advised to contact the screening programme's office on 01384 244177 to rebook an appointment at a more convenient time. Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram.
Reuters
2 hours ago
- Reuters
Health Rounds: Human fetal kidney development mimicked in test tubes
Aug 20 (Reuters) - This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here. Researchers are a step closer to learning how congenital kidney defects develop in the fetus and how they might be prevented, a new report shows. For the first time, they can watch miniature human fetal kidneys develop in test tubes over periods that simulate the course of a pregnancy. So-called kidney organoids have been grown in test tubes before, but only starting with pluripotent stem cells – immature cells found in early embryos that can differentiate into any cell type in the body but without the tissue-specific characteristics that would allow them to perform an organ's specialized functions. In contrast, the new organoids are grown in test tubes using the same fetal progenitor stem cells that are destined to develop into human kidneys. These cells are capable of building, maintaining and repairing specific organs – in this case, the kidneys. While kidney organoids grown from pluripotent stem cells have survived in test tubes for weeks, the new organoids built from the human fetal kidney stem cells can survive and grow for six to eight months, essentially allowing researchers to observe human kidney development as it would happen during a pregnancy, the research team reported in The EMBO Journal, opens new tab. 'Once we had the tissue stem cells coming from the developing human kidney in the Petri dish, they did the job because this is what they do in nature,' said Dr. Benjamin Dekel of Safra Children's Hospital at Sheba Medical Center and Tel Aviv University, who led the research. 'The cells are self-assembling. They know how to self-organize and how to self-renew, (that is) make copies of themselves,' Dekel said. At the same time, Dekel continued, the cells begin to differentiate, developing qualities that make them appropriate for different roles. Researchers can watch as kidney tubules, ducts, blood vessels and other renal tissues are formed. In his clinical practice, Dekel treats children with kidney diseases. He hopes eventually to use the organoids to study kidney malformations and to isolate genes that lead to birth defects, develop new treatments in the field of regenerative medicine and test the toxicity of drugs during pregnancy on fetal kidneys. In the meantime, he said, it's frustrating to watch as patients' chronic kidney disease worsen into end-stage renal disease. 'Then we need to give them a kidney transplant or to put them on dialysis, which is really a very poor solution,' he said. New findings help explain why experimental treatments for cancers caused by human papillomavirus infections have been less than effective, researchers say. The most common cancer-causing strain of HPV undermines the body's defenses by reprogramming immune cells surrounding the tumor, earlier research has shown. Blocking this process can boost the ability of experimental treatments for HPV to eliminate cancer cells, according to a report published in the Journal for ImmunoTherapy of Cancer, opens new tab. While vaccines exist to prevent HPV infections, researchers have failed to develop effective 'therapeutic vaccines' for use after HPV infections have occurred – and the new study helps explain why. Experimental therapeutic vaccines target HPV-infected cells with immune cells known as T-cells. But in tests in mice and cell cultures, researchers found that two HPV proteins, E6 and E7, prompt nearby cells to release a protein called IL-23 that prevents the body's T-cells from attacking the tumor. 'In order to eliminate the cancer, T-cells need to proliferate and destroy infected cells. But IL-23 stops them from working effectively, so the tumor keeps growing,' study leader W. Martin Kast of the Keck School of Medicine of the University of Southern California said in a statement. Drugs that inhibit IL-23 are already approved for treating psoriasis and other conditions, the researchers said. 'The fact that these antibodies are already FDA-approved for something else makes this approach promising — and it also allows for rapid translation into the clinic,' Kast said. He and his team are now developing their own therapeutic vaccine, which they will test in combination with antibodies that block IL-23. IL-23 is also found at high levels in testicular and bladder cancers, the researchers noted, adding that further research is needed to clarify what role IL-23 plays in those diseases. Hearing loss is a known risk factor for dementia, but early intervention might lower that risk, a new study suggests. Researchers performed hearing tests in nearly 3,000 volunteers without dementia who were at least 60 years old. Over the next 20 years, the researchers saw a 61% lower risk for eventual dementia among those with newly diagnosed hearing loss who started wearing hearing aids before age 70, compared to participants diagnosed with hearing impairment at a similar age who did not get hearing aids, they reported in JAMA Neurology, opens new tab. Hearing aid use did not appear to protect against dementia in people diagnosed with a hearing problem after age 70, however. 'Only 17% of individuals with moderate to severe hearing loss use hearing aids,' the researchers noted. 'Our study underscores the importance of early intervention' to reduce the risk of dementia associated with hearing loss, they concluded. To receive the full newsletter in your inbox for free sign up here.
